Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Effect of bleomycin hydrolase expression in tumor tissue on the therapeutic effectiveness of electrochemotherapy
Authors:ID Bogataj, Jan (Author)
ID Lampreht Tratar, Urša (Author)
ID Serša, Gregor (Author)
ID Čemažar, Maja (Author)
ID Grošelj, Aleš (Author)
ID Omerzel, Maša (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/2072-6694/18/1/127
 
.pdf PDF - Presentation file, download (17,01 MB)
MD5: 7F4A99461303C6E3AF4336F6A2DFDCAC
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Electrochemotherapy (ECT) is a cancer treatment that combines application of short electrical pulses with chemotherapy drugs to improve their delivery into tumor cells. Bleomycin is one of the most effective drugs used in ECT, but its success can vary depending on the tumor type. One possible reason is the presence of bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin. In this study, we measured BLMH levels in different mouse tumor cell lines and tumors grown in animals. Thereafter we compared the levels of BLMH with tumor response to ECT and found a correlation with BLMH content, i.e., tumors with higher BLMH content responded poorly. These findings suggest that levels of BLMH could serve as a predictive marker for ECT effectiveness. Testing for BLMH before treatment may help personalize therapy and identify patients most likely to benefit from ECT.
Keywords:electrochemotherapy, bleomycin hydrolase, predictive biomarker, murine models
Publication status:Published
Publication version:Version of Record
Submitted for review:21.11.2025
Article acceptance date:29.12.2025
Publication date:30.12.2025
Place of publishing:Basel
Publisher:MDPI, Basel, Switzerland
Year of publishing:2025
Number of pages:str. 127-1-127-13
Numbering:Vol. 18, no. 1
Source:Basel, Switzerland
PID:20.500.12556/DiRROS-29051 New window
UDC:602
ISSN on article:2072-6694
DOI:10.3390/cancers18010127 New window
COBISS.SI-ID:263366147 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 9. 1. 2026;
Publication date in DiRROS:20.04.2026
Views:95
Downloads:63
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0428-2022
Name:Primerjalna onkologija za obravnavo redkih vrst raka

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:elektrokemoterapija, hidrolaza bleomicina, napovedni biološki označevalci, modeli sesalcev


Back